Home / Stocks / GILD

Gilead Sciences (GILD, Biotechnology) Stock Valuation & Fair Value Significantly overvalued

Gilead Sciences (GILD, Biotechnology) trades at a blended P/E of 86.2, about 472% above its historical normal valuation, with a forward growth estimate above 100% and a PEG of 0.68. Analysts' one-year estimates have been hit 64% of the time. Priced at its historical normal P/E of 15.1 on the same blended earnings, the 2026-10-02 close of $144.74 corresponds to about $25.30 a share. This is a valuation reference, not a price target.

DATA AS OF 2026-10-05
Blended P/E
86.2
Normal P/E
15.1
PEG
0.68
Fwd growth
>100%
Div yield
2.3%
RSI (14)
50.5
Neutral
Technical context
  • Price $147.10 at the 2026-10-08 close, 0.8% below the 20-day average ($148.31) and 2.3% above the 50-day ($143.81).
  • RSI (14) at 50.5.
  • 52-week range $113.92 to $153.05: the price is 3.9% below the high and 29.1% above the low.
  • At its last earnings report the options market priced a 4.3% move.

The Street vs SeerForecast

Wall Street's mean price target for GILD is $158.65 across 26 analysts, 7.9% above the current price. The average analyst rating is Buy. Our SeerForecast read of the same stock, formed without analyst targets: significantly overvalued. When the two disagree, start your digging there.

Valuation flags

Verdict history

tickerseer's rating moved from strong on our tests (2026-06-03) to significantly overvalued (2026-10-05). New rating rules took effect in the week of 2026-09-28, and this rating moved across that change, so part of the move may come from the new rules rather than the company.

Blended P/E and rating by weekBlended P/E moved from 30.0 to 86.2 between 2026-06-03 and 2026-10-02, against a normal P/E of 15.1, with 2 rating changes over 37 recorded weeks.2026-06-03: P/E 30.0, Strong on our tests, recalculated for the week of 2026-06-032026-06-10: P/E 29.7, Strong on our tests, recalculated for the week of 2026-06-102026-06-12: P/E 29.7, Strong on our tests, recalculated for the week of 2026-06-142026-06-16: P/E 29.7, Strong on our tests, recalculated for the week of 2026-06-162026-06-18: P/E 29.7, Strong on our tests, recalculated for the week of 2026-06-212026-07-02: P/E 33.9, Strong on our tests, recalculated for the week of 2026-07-022026-07-06: P/E 35.6, Strong on our tests, recalculated for the week of 2026-07-062026-07-09: P/E 35.6, Strong on our tests, recalculated for the week of 2026-07-092026-07-10: P/E 37.1, Strong on our tests, recalculated for the week of 2026-07-122026-07-13: P/E 37.1, Strong on our tests, recalculated for the week of 2026-07-132026-07-14: P/E 37.1, Strong on our tests, recalculated for the week of 2026-07-142026-07-20: P/E 40.4, Strong on our tests, recalculated for the week of 2026-07-202026-07-22: P/E 40.4, Strong on our tests, recalculated for the week of 2026-07-222026-07-24: P/E 41.0, Strong on our tests, recalculated for the week of 2026-07-252026-07-27: P/E 41.0, Strong on our tests, recalculated for the week of 2026-07-272026-07-31: P/E 43.6, Strong on our tests, recalculated for the week of 2026-07-312026-07-31: P/E 43.7, Strong on our tests, recorded live 2026-08-032026-08-07: P/E 43.6, Favorable on our tests, recalculated for the week of 2026-08-072026-08-07: P/E 44.7, Favorable on our tests, recorded live 2026-08-102026-08-14: P/E 48.6, Favorable on our tests, recalculated for the week of 2026-08-142026-08-14: P/E 48.6, Favorable on our tests, recorded live 2026-08-172026-08-21: P/E 53.5, Favorable on our tests, recalculated for the week of 2026-08-212026-08-21: P/E 54.9, Favorable on our tests, recorded live 2026-08-242026-08-27: P/E 54.9, Favorable on our tests, recalculated for the week of 2026-08-272026-08-28: P/E 59.1, Favorable on our tests, recalculated for the week of 2026-08-282026-08-28: P/E 58.4, Favorable on our tests, recalculated for the week of 2026-08-302026-08-28: P/E 58.4, Favorable on our tests, recorded live 2026-08-312026-09-04: P/E 64.8, Favorable on our tests, recalculated for the week of 2026-09-052026-09-04: P/E 64.8, Favorable on our tests, recorded live 2026-09-072026-09-11: P/E 66.2, Favorable on our tests, recalculated for the week of 2026-09-122026-09-11: P/E 66.2, Favorable on our tests, recorded live 2026-09-142026-09-18: P/E 74.8, Favorable on our tests, recalculated for the week of 2026-09-192026-09-18: P/E 74.8, Favorable on our tests, recorded live 2026-09-212026-09-25: P/E 81.9, Favorable on our tests, recalculated for the week of 2026-09-262026-09-25: P/E 81.9, Significantly overvalued, recorded live 2026-09-282026-10-02: P/E 86.2, Significantly overvalued, recalculated for the week of 2026-10-032026-10-02: P/E 86.2, Significantly overvalued, recorded live 2026-10-0520.040.060.080.0Jun 3Jul 3Aug 2Sep 2Oct 2Normal P/E 15.1
Strong on our testsFavorable on our testsSignificantly overvaluedLarger dot: a stronger reading

Not every point was recorded live. Points marked recalculated apply today's valuation rules to the metrics tickerseer archived that week.

Selected weeks: the first, the latest, every week the rating moved, and the cheapest and dearest.

WeekBlended P/EPremium to normal P/ERating
2026-06-03P/E 30.0+99%Strong on our tests (recalculated)
2026-06-10P/E 29.7+97%Strong on our tests (recalculated)
2026-08-07P/E 43.6+189%Favorable on our tests (recalculated)
2026-09-28P/E 81.9+443%Significantly overvalued (across a rating rules change)
2026-10-03P/E 86.2+472%Significantly overvalued (recalculated)
2026-10-05P/E 86.2+472%Significantly overvalued ← now
Show all 37 weeks
WeekBlended P/EPremium to normal P/ERating
2026-06-03P/E 30.0+99%Strong on our tests (recalculated)
2026-06-10P/E 29.7+97%Strong on our tests (recalculated)
2026-06-14P/E 29.7+97%Strong on our tests (recalculated)
2026-06-16P/E 29.7+97%Strong on our tests (recalculated)
2026-06-21P/E 29.7+97%Strong on our tests (recalculated)
2026-07-02P/E 33.9+125%Strong on our tests (recalculated)
2026-07-06P/E 35.6+136%Strong on our tests (recalculated)
2026-07-09P/E 35.6+136%Strong on our tests (recalculated)
2026-07-12P/E 37.1+146%Strong on our tests (recalculated)
2026-07-13P/E 37.1+146%Strong on our tests (recalculated)
2026-07-14P/E 37.1+146%Strong on our tests (recalculated)
2026-07-20P/E 40.4+168%Strong on our tests (recalculated)
2026-07-22P/E 40.4+168%Strong on our tests (recalculated)
2026-07-25P/E 41.0+172%Strong on our tests (recalculated)
2026-07-27P/E 41.0+172%Strong on our tests (recalculated)
2026-07-31P/E 43.6+189%Strong on our tests (recalculated)
2026-08-03P/E 43.7+189%Strong on our tests
2026-08-07P/E 43.6+189%Favorable on our tests (recalculated)
2026-08-10P/E 44.7+196%Favorable on our tests
2026-08-14P/E 48.6+222%Favorable on our tests (recalculated)
2026-08-17P/E 48.6+222%Favorable on our tests
2026-08-21P/E 53.5+254%Favorable on our tests (recalculated)
2026-08-24P/E 54.9+264%Favorable on our tests
2026-08-27P/E 54.9+264%Favorable on our tests (recalculated)
2026-08-28P/E 59.1+292%Favorable on our tests (recalculated)
2026-08-30P/E 58.4+287%Favorable on our tests (recalculated)
2026-08-31P/E 58.4+287%Favorable on our tests
2026-09-05P/E 64.8+329%Favorable on our tests (recalculated)
2026-09-07P/E 64.8+329%Favorable on our tests
2026-09-12P/E 66.2+338%Favorable on our tests (recalculated)
2026-09-14P/E 66.2+338%Favorable on our tests
2026-09-19P/E 74.8+395%Favorable on our tests (recalculated)
2026-09-21P/E 74.8+395%Favorable on our tests
2026-09-26P/E 81.9+443%Favorable on our tests (recalculated)
2026-09-28P/E 81.9+443%Significantly overvalued (across a rating rules change)
2026-10-03P/E 86.2+472%Significantly overvalued (recalculated)
2026-10-05P/E 86.2+472%Significantly overvalued ← now

Earnings moves: GILD moved more than the options market implied in 0 of 1 recent tracked reports.

Frequently asked questions

Is Gilead Sciences stock overvalued?

At a blended P/E of 86.2 versus its historical normal P/E of 15.1, Gilead Sciences trades about 472% above its typical valuation, with a PEG of 0.68 on forward growth above 100%. tickerseer currently rates it significantly overvalued.

What is Gilead Sciences's fair value and PEG?

Gilead Sciences trades at a blended P/E of 86.2 against a historical normal P/E of 15.1, a PEG of 0.68, and a forward growth estimate above 100%. Priced at its historical normal P/E of 15.1 on the same blended earnings, the 2026-10-02 close of $144.74 corresponds to about $25.30 a share. This is a valuation reference, not a price target.

Has tickerseer's rating of Gilead Sciences changed?

tickerseer's rating moved from strong on our tests (2026-06-03) to significantly overvalued (2026-10-05). New rating rules took effect in the week of 2026-09-28, and this rating moved across that change, so part of the move may come from the new rules rather than the company.

What is the analyst price target for Gilead Sciences?

The mean Wall Street price target for Gilead Sciences is $158.65 across 26 analysts, 7.9% above the current price. tickerseer's SeerForecast verdict is formed independently of analyst targets.

Industry: Biotechnology. Create a free account to see the full analysis: the SeerAI score, its five quality sub-scores, valuation history, and the AI research note. Options setups and metric history are part of the paid plans.

See the full analysis →🔔 Track GILD free: valuation & earnings alerts

Get the free weekly earnings preview

One email each Monday with the week's named earnings setups, the reasoning, and what settled last week. Strikes and sizing stay in Premium.

It's free, and you can unsubscribe any time. We also send a short product update once a month. Educational content, not investment advice.